MD.45 cells transduced to express the scFv(anti-HER-2/neu)/ζ could specifically recognise HER-2/neu+ breast and ovarian tumour cell lines as well as HER-2/neu+ primary tumour cells from patients with metastatic breast and ovarian cancer. This evidence concerns the gene ERBB2 and ovarian carcinoma.